WallStSmart

Danaher Corporation (DHR)vsENDRA Life Sciences Inc (NDRA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DHR leads profitability with a 16.0% profit margin vs 0.0%. DHR earns a higher WallStSmart Score of 66/100 (B-).

DHR

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 4/9Altman Z: 2.36

NDRA

Avoid

18

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -45.23
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DHRSignificantly Overvalued (-66.7%)

Margin of Safety

-66.7%

Fair Value

$117.88

Current Price

$196.22

$78.34 premium

UndervaluedFair: $117.88Overvalued

Intrinsic value data unavailable for NDRA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DHR4 strengths · Avg: 8.8/10
EPS GrowthGrowth
59.7%10/10

Earnings expanding 59.7% YoY

Market CapQuality
$125.93B9/10

Large-cap with strong market position

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$1.26B8/10

Generating 1.3B in free cash flow

NDRA1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.269/10

Conservative balance sheet, low leverage

Areas to Watch

DHR2 concerns · Avg: 3.5/10
P/E RatioValuation
34.7x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

NDRA4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$6.07M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : DHR

The strongest argument for DHR centers on EPS Growth, Market Cap, Price/Book. Profitability is solid with margins at 16.0% and operating margin at 18.0%. PEG of 1.15 suggests the stock is reasonably priced for its growth.

Bull Case : NDRA

The strongest argument for NDRA centers on Debt/Equity.

Bear Case : DHR

The primary concerns for DHR are P/E Ratio, Return on Equity.

Bear Case : NDRA

The primary concerns for NDRA are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

DHR profiles as a mature stock while NDRA is a value play — different risk/reward profiles.

DHR carries more volatility with a beta of 0.82 — expect wider price swings.

DHR is growing revenue faster at 5.5% — sustainability is the question.

DHR generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

DHR scores higher overall (66/100 vs 18/100), backed by strong 16.0% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Danaher Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.

ENDRA Life Sciences Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. The company is headquartered in Ann Arbor, Michigan.

Visit Website →

Want to dig deeper into these stocks?